The pyrogen
testing market was valued at USD 1.35 billion in 2021 and is predicted to grow
at a CAGR of 10% to reach USD 4.6 billion by 2032.
The Pyrogen
Testing market is witnessing steady growth, driven by stringent
regulatory requirements in pharmaceuticals, biotechnology, and medical devices.
With increasing drug development and manufacturing, demand for pyrogen testing
to ensure product safety escalates. Key factors shaping the market include
technological advancements, automation, and rising awareness regarding
healthcare safety standards. The adoption of in vitro methods over in vivo
testing, along with the integration of innovative assays, propels market expansion.
Moreover, emerging economies' investments in healthcare infrastructure
contribute to market dynamics. However, challenges like complex regulatory
frameworks and the high cost of advanced testing methods pose constraints.
Overall, the Pyrogen Testing market shows promising growth prospects.
The Pyrogen
Testing market is witnessing a surge in demand owing to heightened concerns
surrounding pyrogenicity in pharmaceuticals and medical devices. Pyrogens, such
as endotoxins, pose significant risks to human health, triggering pyrogenic
reactions when introduced into the body. As a result, the need for robust
Pyrogen Testing methodologies, including endotoxin pyrogen detection and
Pyrogenic substance analysis, has become paramount across industries.
Endotoxin
pyrogens, originating primarily from bacterial sources, are
pervasive in pharmaceuticals and medical devices. Detecting and quantifying
these pyrogens require advanced techniques capable of identifying minute traces
of pyrogenic substances. Pyrogen Testing methodologies ensure the safety and
efficacy of pharmaceutical products, medical devices, and even sterile medical
equipment.
In the Pyrogen
Testing market, innovative solutions incorporating cutting-edge technologies
are emerging to address the growing demand for precise and reliable testing.
Laboratories and pharmaceutical companies are investing in advanced
instrumentation and methodologies to streamline Pyrogen Testing processes while
adhering to stringent regulatory standards.
Pyrogenicity
evaluation serves as a critical aspect of quality control measures in
pharmaceutical manufacturing, ensuring compliance with regulatory guidelines
and safeguarding patient welfare. As the healthcare industry continues to
prioritize patient safety and product quality, the Pyrogen Testing market is
poised for sustained growth, driven by the increasing emphasis on rigorous
pyrogen detection and analysis techniques.
Segmentation:
MRFR, in their report on the global pyrogen
testing market, segmented the market by product, test type, application
and end-user for a better understanding.
Based on the product, the pyrogen testing
market can be segmented into instruments, services, kits, and reagents.
Based on the test type, the pyrogen testing
market can be segmented into recombinant factor C assay (rFC), limulus
amoebocyte lysate (LAL) test, monocyte activation test (MAT), and rabbit
pyrogen test (RPT). LAL test’s market proliferation is quite intense and its
popularity among the parenteral pharmaceuticals and medical device
manufacturing companies is on the rise.
Based on the application, the pyrogen
testing market can be segmented into pharmaceutical & biologics, medical
devices, and other applications systems.
Based on the end-user, the pyrogen testing market
includes medical device companies, pharmaceutical companies, biotechnology
companies, food and beverage companies. The pharmaceutical company’s segment is
gaining much prominence.
Regional Analysis:
MRFR, in their latest report on the global
pyrogen testing market, included North America, Europe, Asia Pacific (APAC),
and the Middle East & Africa (MEA) for a region-specific analysis.
North America’s dominance in the global
sphere can be attributed to the presence of the U.S. The country has the superlative infrastructure for research &
development and a robust healthcare
system. The presence of several pharmaceuticals and biotech companies are
creating scope for the market to expand with great gusto.
Europe’s dominance
is a tad tinier than that of North America. The presence of several big
names such as France, Germany, the U.K., and others and their substantial
spending in the R & D sector to develop better drug can emerge as one the
major factors pushing the market ahead. The pyrogen testing demand is also
increasing as the immunity in the aged and children are really low and any kind
of secondary disease can adversely impact the healing process.
The emergence of APAC is quite riveting. As
developing economies trying to revamp their healthcare sector, a rise in investment regarding infrastructural
development has become significant. The regional market is quite alluring to
the global players for a number of reasons such as cost-effective resources and
labor.
The MEA market can contribute meagerly to
the global development of pyrogen testing market. The regional market has a poor infrastructure which can be a great
obstacle for the market growth during the forecast period. But a rise in
hospital number can ensure better growth for the pyrogen testing market in the
region.
Competitive
Landscape:
The pyrogen testing market players
are Thermo Fisher Scientific, Inc. (US),
Ellab A/S (UK), Charles River Laboratories, Inc. (US), GenScript (US), Hyglos
GmbH (UK), Merck KGaA (UK), Lonza (UK), Pyrostar (Japan), Wako Chemicals (US),
Sanquin (UK), WuXi PharmaTech (Cayman), Inc (China), Associates of Cape Cod,
Inc. (US), and others.
In 2018, MilliporeSigma declared that they
are ready to collaborate with Solvias to create a new pyrogen testing kit. The
kit would be a cell-line-based Monocyte
Activation Test (MAT) kit.
Related Report:
Automated Suturing Devices Market
For More
Information, Please Visit @ https://www.marketresearchfuture.com/
0 Comments